Boothbay Fund Management LLC Makes New $2.61 Million Investment in Tyra Biosciences, Inc. $TYRA

Boothbay Fund Management LLC acquired a new position in shares of Tyra Biosciences, Inc. (NASDAQ:TYRA) in the 3rd quarter, according to its most recent disclosure with the SEC. The institutional investor acquired 186,670 shares of the company’s stock, valued at approximately $2,612,000. Boothbay Fund Management LLC owned approximately 0.35% of Tyra Biosciences as of its most recent filing with the SEC.

A number of other hedge funds have also made changes to their positions in the business. Ameriprise Financial Inc. increased its stake in Tyra Biosciences by 8.1% in the third quarter. Ameriprise Financial Inc. now owns 87,107 shares of the company’s stock valued at $1,219,000 after purchasing an additional 6,505 shares during the last quarter. Raymond James Financial Inc. boosted its holdings in shares of Tyra Biosciences by 100.0% in the 3rd quarter. Raymond James Financial Inc. now owns 126,374 shares of the company’s stock valued at $1,768,000 after buying an additional 63,187 shares in the last quarter. Caligan Partners LP grew its position in shares of Tyra Biosciences by 266.8% in the 3rd quarter. Caligan Partners LP now owns 696,825 shares of the company’s stock valued at $9,749,000 after buying an additional 506,875 shares during the last quarter. Balyasny Asset Management L.P. raised its stake in Tyra Biosciences by 45.1% during the 3rd quarter. Balyasny Asset Management L.P. now owns 846,585 shares of the company’s stock worth $11,844,000 after acquiring an additional 263,199 shares in the last quarter. Finally, Two Sigma Investments LP raised its stake in Tyra Biosciences by 88.5% during the 3rd quarter. Two Sigma Investments LP now owns 199,438 shares of the company’s stock worth $2,790,000 after acquiring an additional 93,613 shares in the last quarter. Hedge funds and other institutional investors own 84.14% of the company’s stock.

Tyra Biosciences Stock Up 2.2%

TYRA opened at $37.01 on Tuesday. Tyra Biosciences, Inc. has a 52 week low of $6.42 and a 52 week high of $37.84. The business has a 50 day moving average price of $31.41 and a two-hundred day moving average price of $22.27. The company has a market cap of $1.99 billion, a PE ratio of -18.41 and a beta of 1.06.

Tyra Biosciences (NASDAQ:TYRA) last released its earnings results on Monday, March 2nd. The company reported ($0.57) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.54) by ($0.03). As a group, sell-side analysts expect that Tyra Biosciences, Inc. will post -1.57 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of research firms have recently commented on TYRA. Weiss Ratings reiterated a “sell (d-)” rating on shares of Tyra Biosciences in a research report on Wednesday, January 21st. Barclays assumed coverage on Tyra Biosciences in a research note on Tuesday, January 27th. They set an “overweight” rating on the stock. Wedbush lifted their price target on Tyra Biosciences from $37.00 to $53.00 and gave the stock an “outperform” rating in a research report on Friday, February 13th. William Blair initiated coverage on Tyra Biosciences in a research note on Tuesday, February 10th. They issued an “outperform” rating for the company. Finally, Wall Street Zen lowered shares of Tyra Biosciences from a “hold” rating to a “sell” rating in a research report on Saturday, January 24th. One equities research analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $42.33.

Insider Transactions at Tyra Biosciences

In other Tyra Biosciences news, Director Robert J. More sold 10,000 shares of the business’s stock in a transaction on Friday, December 19th. The shares were sold at an average price of $25.00, for a total value of $250,000.00. Following the transaction, the director directly owned 3,823,425 shares of the company’s stock, valued at approximately $95,585,625. The trade was a 0.26% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Corporate insiders own 15.20% of the company’s stock.

About Tyra Biosciences

Tyra Biosciences (NASDAQ: TYRA) is a clinical-stage precision oncology company focused on the discovery and development of small-molecule therapies for genetically defined cancers. The company integrates bioinformatics, molecular biology and medicinal chemistry to identify oncogenic drivers and design targeted inhibitors. By leveraging large-scale genomic datasets and functional screening, Tyra Biosciences aims to advance therapies that address patient populations with high unmet medical need.

The company’s pipeline includes multiple programs at various stages of development, each directed against distinct molecular vulnerabilities in cancer cells.